Welcome to our dedicated page for AnaptysBio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on AnaptysBio stock.
AnaptysBio, Inc. (Nasdaq: ANAB) is a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics to address unmet medical needs. Founded in 2005, AnaptysBio leverages its proprietary SHM-XEL platform to generate high-affinity therapeutic antibodies by harnessing the natural process of somatic hypermutation (SHM) under controlled conditions. The SHM-XEL platform mimics key features of the human immune system and overcomes the limitations of prior antibody technologies.
Headquartered in San Diego, AnaptysBio is focused on creating a robust pipeline of novel therapeutic antibody candidates targeting autoimmune, inflammatory, and oncology indications. The company boasts a portfolio that includes clinical-stage immune cell modulators such as rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist), both in Phase 2 trials for rheumatoid arthritis (RA), ulcerative colitis (UC), and atopic dermatitis (AD).
AnaptysBio has shown significant progress in its clinical programs. Notably, the company reported positive top-line results from its global Phase 3 GEMINI-1 and GEMINI-2 trials evaluating imsidolimab (IL-36R mAb) for generalized pustular psoriasis (GPP). The results demonstrated rapid clearance of GPP symptoms with a single intravenous dose followed by effective maintenance with monthly subcutaneous doses.
Financially, AnaptysBio is on solid ground, reiterating a cash runway through year-end 2026 with expected year-end 2023 cash and investments of $400 to $410 million. The company's strategic collaborations, including its partnership with GSK for Jemperli (dostarlimab-gxly), provide additional financial support and validation of their therapeutic candidates' commercial potential.
Recently, AnaptysBio announced an exclusive license agreement with Centessa Pharmaceuticals for a BDCA2 modulator portfolio, including ANB101, further expanding its pipeline. The company plans to submit investigational new drug (IND) applications for ANB033 (anti-CD122 antagonist) and ANB101 in 2024.
With a commitment to patient-centric innovation and a strategic approach to partnerships and financial management, AnaptysBio continues to advance its mission of delivering transformative therapies to improve patients' lives globally.
AnaptysBio (ANAB) announced that its Phase 2b ARISE-AD trial of ANB032, a BTLA agonist, failed to meet primary and secondary endpoints in treating moderate-to-severe atopic dermatitis. The study involved 201 patients across multiple countries, testing different dosing regimens against placebo. Despite ANB032 showing good tolerability with no safety concerns, the company will discontinue further investment in this asset.
The company will now focus on its remaining autoimmune portfolio, including rosnilimab, with Phase 2b rheumatoid arthritis data expected in February 2025 and Phase 2 ulcerative colitis data in Q1 2026. AnaptysBio maintains a strong financial position with approximately $415 million in cash by year-end 2024, extending their runway through 2027.
AnaptysBio (ANAB) has announced its participation in four major healthcare investor conferences during November and December 2024. The company's president and CEO Daniel Faga, along with senior management, will participate in fireside chats and one-on-one investor meetings at Guggenheim's Healthcare Innovation Conference (Nov. 13), Stifel Healthcare Conference (Nov. 19), Piper Sandler Healthcare Conference (Dec. 3), and Evercore HealthCONx Conference (Dec. 4). Live webcasts will be available on the company's investor website with replays accessible for 30 days after the events.
AnaptysBio reported Q3 2024 financial results and business updates. The company anticipates top-line Phase 2b data for ANB032 in atopic dermatitis in December 2024 and for rosnilimab in rheumatoid arthritis in February 2025. Cash position stands at $458.0 million, with runway through year-end 2026. Q3 collaboration revenue increased to $30.0 million, while net loss was $32.9 million ($1.14 per share). R&D expenses rose to $42.2 million, primarily due to development costs for key pipeline programs. The company initiated a Phase 1 trial for ANB033 and plans to out-license imsidolimab in 2024.
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA on Sept. 5 at 10:15am ET
2. Stifel 2024 Virtual Immunology and Inflammation Summit on Sept. 17 at 1:30pm ET
3. 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Sept. 18 at 9:45am ET
The company's president and CEO, Daniel Faga, and/or other senior management team members will participate in fireside chats and one-on-one investor meetings. Live webcasts of the fireside chats will be available on the Anaptys website, with replays accessible for at least 30 days after the events.
AnaptysBio (ANAB) has announced the pricing of an underwritten offering of 2,750,498 shares of common stock at $36.50 per share, a 10% premium to the previous closing price. The offering, led by EcoR1 Capital with participation from existing and new investors including Sanofi, is expected to raise approximately $100 million in gross proceeds. The funds will primarily be used to accelerate Phase 3 trials for ANB032 (BTLA agonist) in atopic dermatitis and rosnilimab (PD-1 agonist) in rheumatoid arthritis and ulcerative colitis. The offering is set to close around August 15, 2024, subject to customary conditions. TD Cowen, Leerink Partners, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the offering.
Anaptys (NASDAQ: ANAB) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Completed enrollment for Phase 2b trial of ANB032 in atopic dermatitis, with top-line data expected in December 2024.
2. Accelerated top-line data for Phase 2b trial of rosnilimab in rheumatoid arthritis to Q1 2025.
3. FDA accepted IND for ANB033, with Phase 1 trial initiation anticipated in Q4 2024.
4. Cash and investments of $393.5 million as of June 30, 2024.
5. Q2 2024 net loss of $46.7 million, or $1.71 per share.
The company remains on track to have four immune cell modulators in clinical development by year-end.
AnaptysBio, Inc. (Nasdaq: ANAB) reported financial results for Q1 2024, highlighting progress in Phase 2 trials for ANB032 and rosnilimab, with top-line data expected late 2024 and mid 2025, respectively. IND submissions for ANB033 and ANB101 planned for 2024. Positive Phase 3 trial results for imsidolimab. $50 million revenue from royalty monetization. Cash, cash equivalents, and investments at $370.1 million as of March 31, 2024, with a cash runway through 2026. Collaboration revenue increased to $7.2 million. Research and development expenses up, net loss of $43.9 million.
AnaptysBio, Inc. announces positive top-line results from GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab in treating generalized pustular psoriasis (GPP). Patients showed significant improvements in skin clearance with minimal flares. The company plans to out-license imsidolimab in 2024 after demonstrating favorable safety and tolerability profiles.
AnaptysBio, a biotech company, is set to receive $50 million upfront cash payment from Sagard Healthcare as part of an amended agreement. The agreement involves additional royalties for Anaptys Jemperli, with Sagard potentially paying either $600 million by March 31, 2031, or $675 million thereafter. The funds will be used for the development of immune cell modulators in autoimmune and inflammatory diseases, strengthening Anaptys' balance sheet and supporting clinical programs.
FAQ
What is the current stock price of AnaptysBio (ANAB)?
What is the market cap of AnaptysBio (ANAB)?
What does AnaptysBio specialize in?
What are the key clinical programs of AnaptysBio?
What recent achievements has AnaptysBio reported?
What are AnaptysBio's financial highlights?
What is the SHM-XEL platform?
Who are AnaptysBio's strategic partners?
What is the focus of AnaptysBio's preclinical immune cell modulator portfolio?
How does AnaptysBio's SHM-XEL platform benefit their antibody development?
What are the recent licensing agreements by AnaptysBio?
What are AnaptysBio's plans for 2024?
